2005
DOI: 10.1186/1472-6963-5-30
|View full text |Cite
|
Sign up to set email alerts
|

Reactions to treatment debriefing among the participants of a placebo controlled trial

Abstract: Background: A significant proportion of trial participants respond to placebos for a variety of conditions. Despite the common conduct of these trials and the strong emphasis placed on informed consent, very little is known about informing participants about their individual treatment allocation at trial closure. This study aims to address this gap in the literature by exploring treatment beliefs and reactions to feedback about treatment allocation in the participants of a placebo-controlled randomized clinica… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

1
30
0

Year Published

2006
2006
2016
2016

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 31 publications
(31 citation statements)
references
References 26 publications
1
30
0
Order By: Relevance
“…Others have similarly suggested that patients should be informed of the possible effects of placebos at the informed consent stage, so that they focus on these possible effects rather than seeing the placebo as merely a “dummy” treatment (Di Blasi et al, 2005; Fassler et al, 2009). RCT participants may be open to viewing placebos in more positive ways, as this would be broadly consistent with the therapeutic misconception: offering two treatments that can give health benefits (compared to offering one such treatment and one “dummy” treatment) is more consistent with the idea that trial personnel and procedures are interested in achieving health benefits for the individual participant as well as conducting scientific research.…”
Section: Discussionmentioning
confidence: 99%
“…Others have similarly suggested that patients should be informed of the possible effects of placebos at the informed consent stage, so that they focus on these possible effects rather than seeing the placebo as merely a “dummy” treatment (Di Blasi et al, 2005; Fassler et al, 2009). RCT participants may be open to viewing placebos in more positive ways, as this would be broadly consistent with the therapeutic misconception: offering two treatments that can give health benefits (compared to offering one such treatment and one “dummy” treatment) is more consistent with the idea that trial personnel and procedures are interested in achieving health benefits for the individual participant as well as conducting scientific research.…”
Section: Discussionmentioning
confidence: 99%
“…The question of whether research participants should routinely be provided with individualised data is an important one that requires further exploration, particularly given the strength of feeling expressed in our study. Research activity and debate around the issue of treatment debriefing are increasing,20 although there are as yet no signs of an emerging consensus on best practice. In the area of genetic epidemiology, current international guidance21 says that, in general, participants should not be provided with information on their genotype.…”
Section: Discussionmentioning
confidence: 99%
“…The few studies referring to hope parenthetically note that it is often mentioned by patients when asked about their expectations, but is not easily defined or investigated. 4-6 Several researchers have pointed out that conceptualizing hope as a type of expectation is problematic and that increased conceptual clarity is needed. 7-9 The goal of the present analysis is to explore hope in the context of the lived experience of chronic pain.…”
Section: Introductionmentioning
confidence: 99%